Wind River Studio Enabling Hyundai Mobis and Hyundai AutoEver to Accelerate Development of Next-Gen Intelligent and Connected Vehicles
3.5.2022 13:00:00 EEST | Business Wire | Press release
Wind River®, a global leader in delivering software for mission-critical intelligent systems, today announced that Hyundai Mobis, one of the world’s largest vehicle technology innovators and suppliers, and Hyundai AutoEver has signed an agreement to establish a strategic relationship that includes collaboration with Wind River Studio for the development of an automotive software framework and continuous test and test automation capabilities, as well as advanced software lifecycle management.
“As we move toward a more connected and autonomous future, software is at the center of enabling that reality,” said Avijit Sinha, chief product officer, Wind River. “Wind River Studio can help automotive leaders such as Hyundai Mobis and Hyundai AutoEver achieve a modernized development framework across cloud and edge, combined with software lifecycle management capability to enable them to accelerate their innovation and advance the software defined vehicle.”
“Hyundai Mobis plans to continue to introduce new services by adding future mobility technology to intelligent vehicles through extensive cooperation,” said Chang Jae-ho, senior vice president at Hyundai Mobis.
“Hyundai AutoEver plays the role of software specialist in the Hyundai Motor Group and is leading the team towards digital transformation to revolutionize software development and verification processes throughout vehicle development,” said Kim Seong-woon, vice president, head of the Software Quality Innovation Division at Hyundai AutoEver. “Through close cooperation with Wind River, we will strengthen the function and efficiency of Hyundai AutoEver’s software integrated development environment platform and virtual verification platform to contribute to innovation in vehicle software development by Hyundai Mobis and group companies.”
The auto industry is amid its most significant revolution in more than 100 years. Research from Forbes indicates that automotive leaders believe an intelligent systems approach is central to strategies that can deliver up to a 30% growth in revenue opportunities, and in five years’ time, many of the core requirements for intelligent systems in this industry will need to be in place.1
The collaboration will leverage each company’s specialties and experiences to develop a best-in-class software development infrastructure for next-generation connected automobiles. The companies will work closely on methodologies to accelerate the development and delivery of automotive systems, including enhanced continuous test capabilities and test automation in both simulated and real hardware-based environments and new customer test infrastructures making use of virtual device management.
The Hyundai AutoEver team will play a key role working with Wind River on a software integrated development environment platform and virtual verification platform.
Studio provides a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems. Studio delivers a full lifecycle management platform for intelligent systems at cloud scale. Studio enables development workflows that reduce development costs and accelerate capabilities for building, testing, and deploying on the edge.
More information about Wind River Studio is available at www.windriver.com/studio.
About Wind River
Wind River is a global leader in delivering software for mission-critical intelligent systems. For 40 years, the company has been an innovator and pioneer, powering billions of devices and systems that require the highest levels of security, safety, and reliability. Wind River software and expertise are accelerating digital transformation across industries, including automotive, aerospace, defense, industrial, medical, and telecommunications. The company offers a comprehensive portfolio supported by world-class professional services and support and a broad partner ecosystem. To learn more, visit Wind River at www.windriver.com.
About Hyundai MOBIS
Hyundai Mobis is the no.7 global automotive supplier, with annual sales of nearly $30 billion USD. The company was founded in 1977 and is headquartered in Seoul, Korea. Hyundai Mobis aims to become a lifelong technology partner for vehicles and people. The company has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics.
About Hyundai AutoEver
Hyundai AutoEver, a mobility software provider that reliably, efficiently, and innovatively supports software and infrastructure across in-car and out-car areas, builds a mobility software platform to flexibly connect hardware and software, and is creating new value for the upcoming mobility ecosystem.
1 Forbes/Wind River, “Characteristics of Intelligent Systems,” 2021
Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005428/en/
Contact information
Jenny Suh
Wind River
510-749-2972
jenny.suh@windriver.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom